Innovative Eyewear (NASDAQ:LUCY) & Haemonetics (NYSE:HAE) Head-To-Head Survey

Innovative Eyewear (NASDAQ:LUCY) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Innovative Eyewear and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-225.26%	-88.90%	-80.34%
Haemonetics	7.12%	27.55%	9.65%

Insider & Institutional Ownership

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Innovative Eyewear and Haemonetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1	1	0	0	1.50
Haemonetics	0	4	6	1	2.73

Haemonetics has a consensus target price of $99.78, indicating a potential downside of 3.61%. Given Haemonetics’ stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than Innovative Eyewear.

Earnings and Valuation

This table compares Innovative Eyewear and Haemonetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$3.41 million	2.36	-$7.59 million	($1.29)	-0.72
Haemonetics	$1.35 billion	3.48	$97.31 million	$2.04	50.74

Haemonetics has higher revenue and earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Innovative Eyewear has a beta of 2.74, meaning that its stock price is 174% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Summary

Haemonetics beats Innovative Eyewear on 14 of the 15 factors compared between the two stocks.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.